Table 5 from Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use | Semantic Scholar
Table 1 from Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention | Semantic Scholar
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial - ScienceDirect
30570-9.fp.png "THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL | Journal of the American College of Cardiology")
THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL | Journal of the American College of Cardiology
TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com
Efficacy outcomes at 30 days in CHAMPION-PHOENIX trial. | Download Table
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Cangrelor Superior to Clopidogrel in CHAMPION PHOENIX Trial | DAIC
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute€Coronar
Figure1 | THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | JACC: Journal of the American College of Cardiology
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX | tctmd.com
Table 3 from Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. | Semantic Scholar
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Pro Position: The Data - Phoenix and Meta-Analysis of the Champion Clinical Trial Program! | tctmd.com
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial | Journal of the American College of Cardiology
Consistent Reduction in MI with Cangrelor Deepak L - ppt download
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington, - ppt download
CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events | tctmd.com
Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
